Di Nuzzo Private Wealth, Inc. Halozyme Therapeutics, Inc. Transaction History
Di Nuzzo Private Wealth, Inc.
- $658 Million
- Q2 2025
A detailed history of Di Nuzzo Private Wealth, Inc. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Di Nuzzo Private Wealth, Inc. holds 14 shares of HALO stock, worth $869. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14
Previous 15
6.67%
Holding current value
$869
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding HALO
# of Institutions
581Shares Held
123MCall Options Held
308KPut Options Held
186K-
Black Rock Inc. New York, NY17.6MShares$1.09 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$797 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$376 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$242 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$228 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.65B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...